Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several key dosing/titration details and a GI risk causality statement are not supported by the provided FDA label excerpts. A few administration/storage and missed-dose instructions are supported.
Category Scores
Accurate Statements
After a missed dose, Ozempic should be administered as soon as possible within 5 days; if more than 5 days have passed, the missed dose should be skipped and the next regularly scheduled dose resumed.
2.1 Important Administration Instructions (missed dose within 5 days; if >5 days, skip and administer next on regularly scheduled day).
Ozempic should not be doubled up after a missed dose.
2.1 Important Administration Instructions (skip missed dose if >5 days have passed; administer next dose on regularly scheduled day).
Ozempic pens should be stored in the refrigerator at 36–46°F (2°C to 8°C) prior to first use, and can also be stored at 36–46°F after first use.
16 How Supplied/Storage and Handling (2°C to 8°C (36°F to 46°F)).
After first use, in-use Ozempic pens can be stored for 56 days at controlled room temperature (15°C to 30°C; 59°F to 86°F).
16 How Supplied/Storage and Handling (56 days at controlled room temperature 15°C to 30°C).
Ozempic is injected subcutaneously into the abdomen, thigh, or upper arm.
2.1 Important Administration Instructions (inject subcutaneously in abdomen, thigh, or upper arm).
Injection sites should be rotated (use a different injection site each week when injecting in the same body region).
2.1 Important Administration Instructions (use a different injection site each week when injecting in the same body region).
Unsupported Statements
Ozempic starts at a dose of 0.25 mg injected subcutaneously once weekly for the first 4 weeks.
Provided excerpts indicate 0.25 mg is an 'Initiation' dose but do not state a 4-week duration for initiation.
The initial 0.25 mg dose helps patients adjust and reduces gastrointestinal side effects like nausea.
No provided label excerpts state that the 0.25 mg initiation dose reduces nausea or other GI side effects.
After 4 weeks, the dose of Ozempic is increased to 0.5 mg weekly.
Provided excerpts list 0.5 mg as 'Maintenance' but do not specify a 4-week timing for the increase.
If needed for better blood sugar control, doctors may raise Ozempic to 1 mg weekly after at least 4 more weeks.
No provided label excerpt specifies titration to 1 mg, the 'at least 4 more weeks' interval, or that rationale as 'better blood sugar control'.
If needed for better blood sugar control, doctors may raise Ozempic to 2 mg weekly after another 4 weeks.
No provided label excerpt specifies titration to 2 mg, the 'another 4 weeks' interval, or that rationale as 'better blood sugar control'.
Skipping the 0.25 mg initiation or ramping up too fast increases the risk of nausea, vomiting, or diarrhea.
Provided excerpts discuss GI adverse reactions and missed-dose instructions but do not state that skipping initiation or rapid ramping increases specific GI symptoms.
No shaking is needed for Ozempic.
No provided label excerpt includes an instruction about shaking.
Contradictions
Important Omissions
No labeling-backed details were provided about additional administration instructions (e.g., inspecting for particulates/appearance, 'same day each week', and guidance on changing the day with at least 2 days between doses).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and/or not-explicit titration timing/rationale claims (including causal GI risk from skipping initiation/rapid ramping) could lead to inaccurate dosing decisions relative to the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple dosing/titration and causality statements are not supported by the provided label excerpts.
Suggested Improvement
Limit claims to label-excerpt-supported items (missed-dose rule, route/sites, site rotation, and provided storage durations/temperatures). Remove unsupported initiation duration/titration timing and remove GI risk causality statements not present in the provided excerpts.